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The Implication of Coronary Artery Calcium Testing for 
Cardiovascular Disease Prevention and Diabetes 
Ron Blankstein1,2, Ankur Gupta1,2, Jamal S. Rana3,4, Khurram Nasir5,6
1Division of Cardiovascular Medicine, Department of Medicine, 2Department of Radiology, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, MA; Divisions of 3Cardiology, 4Research, Kaiser Permanente Northern California, Oakland, 
CA; 5Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL; 6Miami 
Cardiac & Vascular Institute, Baptist Health South Florida, Miami, FL, USA
Over the last two decades coronary artery calcium (CAC) scanning has emerged as a quick, safe, and inexpensive method to detect 
the presence of coronary atherosclerosis. Data from multiple studies has shown that compared to individuals who do not have any 
coronary calcifications, those with severe calcifications (i.e., CAC score >300) have a 10-fold increase in their risk of coronary heart 
disease events and cardiovascular disease. Conversely, those that have a CAC of 0 have a very low event rate (~0.1%/year), with 
data that now extends to 15 years in some studies. Thus, the most notable implication of identifying CAC in individuals who do not 
have known cardiovascular disease is that it allows targeting of more aggressive therapies to those who have the highest risk of hav-
ing future events. Such identification of risk is especially important for individuals who are not on any therapies for coronary heart 
disease, or when intensification of treatment is being considered but has an uncertain role. This review will highlight some of the re-
cent data on CAC testing, while focusing on the implications of those findings on patient management. The evolving role of CAC in 
patients with diabetes will also be highlighted.
Keywords: Atherosclerosis; Coronary artery disease; Diabetes; Prevention and control 
WHAT IS CORONARY ARTERY CALCIUM?
As opposed to risk factors which tell us the risk someone might 
have of having disease, the detection of calcium in the coronary 
arteries shows us actual evidence of the disease that we are in-
terested in treating or preventing. Thus, individuals who have 
coronary artery calcifications do, in fact, have coronary artery 
disease. However, such disease is often termed as “subclinical” 
as it is most often detected in asymptomatic individuals and is 
not associated with any clinical symptoms (Fig. 1).
PROGNOSTIC VALUE OF THE PRESENCE 
AND ABSENCE OF CORONARY ARTERY 
CALCIUM 
There is substantial evidence to support the fact that among in-
dividuals who do not have known cardiovascular disease 
(CVD), the presence and severity of coronary artery calcium 
(CAC) provides the strongest measure of future cardiovascular 
risk. When compared to individuals who do not have any CAC, 
those with severe calcifications (i.e., CAC score >300) have a 
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10-fold increase in their risk of coronary heart disease (CHD) 
and CVD events (Fig. 2) [1].
CAC scoring can independently predict cardiovascular 
events, and when compared to traditional risk factors, offers im-
proved discrimination and reclassification [2-5]. Indeed, several 
large and well-conducted observational studies have demon-
strated that when added to standard risk prediction models, 
CAC has a significantly greater improvement in risk prediction 
compared with other novel biomarkers or a combined biomark-
er panel [6-8]. Specifically, among intermediate risk patients, 
the addition of CAC to the Framingham risk score has been 
found to have a high net reclassification improvement (66%), 
with most other novel risk markers—such as carotid intima-me-
dia thickness, brachial flow mediated dilation, ankle brachial in-
dex, and high-sensitivity C-reactive protein—having a net re-
classification improvement index of <10%.
Importantly, the superior predictive capabilities of CAC scor-
ing are due to its ability to correctly reclassify patients to both 
high and low risk categories. In particular, individuals who do 
not have any coronary artery calcifications (CAC=0) have an 
extremely low risk of cardiovascular events of approximately 
Fig. 1. Conceptual frameworks of how the presence or absence of 
coronary artery calcium (CAC) may influence patient management. 
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Fig. 2. Unadjusted Kaplan-Meier cumulative-event curves for coro-
nary events among participants with coronary artery calcium scores 
of 0, 1 to 100, 101 to 300, and more than 300. The figure shows the 
rates for any coronary event. The differences among all curves are 
statistically significant (P<0.001). Adapted from Detrano et al. [1], 
with permission from Massachusetts Medical Society.
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Fig. 3. Relationship between pretest and posttest cardiovascular 
disease (CVD) risk after the knowledge of the negative result of 
each risk marker. The regression lines display the relationship be-
tween the pretest predicted 10-year atherosclerotic CVD risk (x 
axis) and the posttest risk (y axis) after the knowledge of the nega-
tive result of each risk marker. A broken back line is displayed as 
reference (risk shift with no additional testing). Results were ob-
tained by plotting the pretest and posttest risk on the basis of the di-
agnostic likelihood ratio of each Multi-Ethnic Study of Atheroscle-
rosis (MESA) participant and then applying a linear fit. Adapted 
from Blaha et al. [10], with permission from Wolters Kluwer 
Health, Inc. CAC, coronary artery calcium; BNP, brain natriuretic 
peptide; CIMT, carotid intima-media thickness; CHD, coronary 
heart disease; ABI, ankle brachial index; hs-CRP, high-sensitivity 
C-reactive protein.
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0.1% per year [9]. The ability of CAC to as a “negative risk 
marker” has been compared to multiple other risk factors among 
participants in the Multi-Ethnic Study of Atherosclerosis 
(MESA) [10]. In this study a CAC of 0 was found to result in 
the greatest downward shift in cardiovascular risk (Fig. 3). 
Much attention has been focused on the utility of CAC scor-
ing to enhance risk prediction for individuals at intermediate 
risk. However, it is important to note that CAC has significant 
prognostic value across a wide spectrum of age and risk factor 
profiles [4,11]. For instance, a prior study by Blankstein et al. [3] 
examined individuals from MESA with low-density lipoprotein 
(LDL) cholesterol ≤130 mg/dL, and showed that the presence 
or absence of CAC was a strong predictor of incident CHD and 
CVD events, regardless of whether other risk factors were pres-
ent or absent (Fig. 4). Among individuals traditionally classified 
as low risk, either based on risk factor burden or calculated risk 
score, a high CAC score (≥100) is associated with an estimated 
10-year all CHD event rate of nearly 10%. In contrast, among 
individuals traditionally identified as high risk by risk factor 
burden or by the Framingham risk score, a CAC score of 0 is as-
sociated with a remarkably low 10-year all CHD event rate of 
roughly 3%. In fact, individuals with no risk factors and an ele-
vated CAC score have nearly three times the event rate of those 
individuals with multiple risk factors and a CAC score of 0 [4].
WHEN IS CAC TESTING MOST HELPFUL? 
While many potential indications exist, in our experience the 
following groups of patients commonly benefit from statin ther-
apy. 
(1)  Statin candidates averse to treatment: patients who are ad-
vised, by guidelines, to be on statin therapy (atherosclerotic 
cardiovascular disease [ASCVD] risk score >5% per the 
pooled cohort equation recommended by the American Col-
lege of Cardiology/American Heart Association [ACC/
AHA]) but who prefer to avoid such therapy.
(2)  Statin intolerant patients: several studies have suggested that 
many individuals who previously were deemed as statin in-
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Fig. 4. Cumulative incidence of coronary heart disease events among Multi-Ethnic Study of Atherosclerosis (MESA) participants with low 
low-density lipoprotein cholesterol (<130 mg/dL) stratified by the presence or absence of diabetes, hypertension as well as the presence or 
absence of coronary artery calcium (CAC). (A) No diabetes, (B) diabetes, (C) no hypertension, and (D) hypertension. Adapted from Blank-
stein et al. [3].
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tolerant may be able to tolerate statins when re-challenged. 
While many such individuals prefer not to be on statins, the 
identification of coronary plaque may serve as a signal to re-
consider a statin, recognizing the greater benefits of such 
therapies in patients who have higher risk. 
(3)  Patients with premature family history of CHD: such indi-
viduals may benefit from more personalized risk assessment 
since most traditional risk equations do not include family 
history of premature CHD. Importantly, even when a strong 
family history is present, the actual burden of CAC—and 
thus a person’s risk—may be highly variable [12].
USE OF CAC IN LIGHT OF RECENT 
GUIDELINES?
Recent data has evaluated how CAC testing may complement 
the recent recommendations made by the European Society of 
Cardiology (ESC) and the AHA/ACC guidelines for use of 
statin therapy in primary prevention of CVD. Nasir et al. [13] 
evaluated how the absence of CAC can be used to downward 
reclassify individuals who are recommended for statin therapy 
by the AHA/ACC guidelines to a lower risk group who may de-
fer such therapy. They applied the AHA/ACC guidelines to 
4,758 participants of the MESA study, of which 50% were rec-
ommended by guidelines to be treated with moderate to high in-
tensity statins. Among those individuals recommended for statin 
therapy, 41% had no CAC (Fig. 5A). Importantly, in the absence 
of CAC, those individuals who had a baseline 10-year ASCVD 
risk score between 7.5% to 20% had an observed 10-year risk 
of 4.6%, which is lower than the 5% threshold used by the 
guidelines for considering or recommending statins. On the oth-
er hand, among individuals who at baseline had an ASCVD risk 
of >20% and CAC=0, a high risk was observed (11.7%), while 
those who had a baseline ASCVD risk below <5% had a low 
event rate irrespective of whether CAC was present or absent 
(Fig. 5B). Based on these results, the role of CAC testing seems 
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greatest among individuals who are considered or recommend-
ed statins, and have an ASCVD risk of 5% to 20%. In such sce-
narios, the absence of CAC can be used to identify a low risk 
group in which statin therapy may be deferred, particularly if 
such an option is preferred by patients and/or physicians based 
on evaluating the risk/benefit of treatment in the setting of low 
risk, while also incorporating patient values and preferences. 
A similar analysis was recently preformed by Mahabadi et al. 
[14], who applied both AHA/ACC guidelines and the ESC 
guidelines to participants of the Heinz Nixdorf Recall study. 
Similar to MESA, this study is a prospective cohort of individu-
als who did not have any known CVD at baseline. This study 
found that for both guidelines, and irrespective of statin indica-
tion, individuals with higher CAC scores had a higher CHD and 
CVD event rate (Fig. 6) [14]. Notably, CAC was absent in 43% 
of individuals who were met statin indications by the ESC 
guidelines and 53% of the individuals who met statin indication 
by the AHA/ACC guidelines. 
WHEN IS CAC TESTING NOT HELPFUL?
Individuals who have known CHD, or who are already on ag-
gressive medical therapy to prevent CVD, are unlikely to bene-
fit from CAC testing. Such individuals are unlikely to have any 
meaningful changes in their management as a result of CAC 
testing. In addition, patients who are averse to treatment, and 
who are unlikely to initiate treatment even if CAC is identified, 
should not undergo CAC testing. 
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WHAT ARE THE LIMITATIONS OF CAC 
TESTING? 
CAC scanning is associated with a low level of radiation, esti-
mated at 1 to 2 mSV, which is equivalent to the dose of a mam-
mogram [15]. CAC scanning cannot be used to follow treatment 
response, as CAC does not regress, and may even progress with 
statin therapy. When CAC testing is performed, incidental find-
ings (e.g., lung nodules) may be found, and these can result in 
additional downstream costs when further investigations are re-
quired. 
WHAT SHOULD BE DONE WHEN CAC IS 
ELEVATED?
Table 1 lists some of the recommended interventions to consider 
for individuals who are found to have elevated CAC. In addi-
tion to initiation of statin therapy, individuals with CAC >100 
are also likely to benefit from aspirin therapy (Fig. 7) [16]. In-
formation on CAC burden, when combined with other clinical 
risk factors, may also inform how aggressive to treat individuals 
with pre-hypertension or hypertension [17].
WHAT PREDICTS THE DEVELOPMENT OF 
CAC LATER IN LIFE?
The Coronary Artery Risk Development in Young Adults 
(CARDIA) study examined the association of various risk fac-
tors in young adults with incident CAC 15 to 25 years later. This 
study found that the levels of modifiable risk factors in young 
adults predicted incident CAC in middle age. Similarly, longer 
duration of overall obesity (e.g., body mass index ≥30) or ab-
dominal obesity was associated with greater CAC progression 
later in life [18]. While these findings support the fact that the 
development of atherosclerosis if often preceded by a constella-
tion of unfavorable risk factors, there is no model which reliably 
predicts the development or absence of CAC and it has been es-
tablished that even among individuals who do not have any tra-
ditional risk factors, the presence of CAC signified elevated risk 
of both CHD and CVD events [4,19].
A recent important finding from the CARDIA study is that 
the presence of any CAC in early adult life (i.e., CAC >0), even 
after accounting for other risk factors, indicates a higher risk of 
having a future CHD or CVD event during the next decade [20]. 
Since the presence of CAC in young adults aged 32 to 46 was 
relatively rare (~10%), widescreen unselected CAC testing in 
those less than 45 is not recommended. However, future studies 
are needed to identify which young individuals are most likely 
to benefit from CAC screening. However, the fact that CAC 
prevalence significantly increases in the third to fifth decade of 
life suggests that this is a particularly important time period to 
implement preventive measures [21].
DOES CAC TESTING IMPROVE 
OUTCOMES?
Some have proposed a large prospective randomized controlled 
Table 1. Recommended Interventions to Prevent Cardiovascular 
Disease Based on CAC Score
CAC=0 CAC >0
Lifestyle changes Lifestyle changes
Guideline directed care of all mod-
ifiable risk factors
Guideline directed care of all mod-
ifiable risk factors
Statin therapy may be deferred if 
patient preference to avoid, and 
10-year risk of ASCVD is <20%
Moderate to severe intensity statin 
therapy, especially if CAC ≥100
Consider aspirin therapy if CAC ≥
100
CAC, coronary artery calcium; ASCVD, atherosclerotic cardiovascular 
disease.
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Fig. 7. Estimated risk/benefit of aspirin in primary prevention by 
coronary artery calcium (CAC) score in Multi-Ethnic Study of Ath-
erosclerosis (MESA) participants. Coronary heart disease (CHD) 
risk was calculated using the Framingham Risk Score. The red line 
represents the estimated 5-year number needed to harm based on a 
0.23% increase in major bleeding over 5 years. The 5-year number 
needed to treat estimations is based on an 18% relative reduction in 
coronary heart disease events. Adapted from Miedema et al. [16], 
with permission from Wolters Kluwer Health, Inc.
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trial (RCT) showing the impact of CAC testing on patient out-
comes. Such a study is unlikely to occur in the current era where 
statins are increasingly being used for prevention. The challeng-
es with a CAC RCT trial are also inherent in the fact that it 
would be unethical to randomized patients that have severe 
amount of CAC into an arm of no therapy. It is also noteworthy, 
that such trial data is also not available for any risk scores, 
which have been proposed for evaluating patients with suspect-
ed CAD.
Nevertheless, there are a few insights that that were highlight-
ed by prior studies. In the St. Francis Heart study, 1,005 asymp-
tomatic, apparently healthy men and women age 50 to 70 years 
with CAC scores ≥80th percentile for age and gender were ran-
domized to atorvastatin 20 mg daily in addition to vitamins C 
and E in a double-blind placebo-controlled trial [22]. After a 
mean follow-up of 4.3 years, treatment with atorvastatin re-
duced LDL cholesterol levels by nearly 40% and showed a 
trend towards reduction in atherosclerotic CVD events (6.9% 
vs. 9.9% in atorvastatin vs. placebo arms respectively, P=0.08). 
The effect of atorvastatin on CVD event reduction was stronger 
in the subgroup of patients with CAC >400 (8.7% vs. 15%, 
P=0.046). This study, while small when compared to contem-
porary trials, and clearly underpowered, provides an important 
signal that patients with increased CAC are most likely to bene-
fit from cholesterol lowering therapies. 
When evaluating the impact of CAC testing on patient out-
comes it is important to consider the various mechanisms by 
which CAC testing may improve outcomes, including both 
pharmacological and non-pharmacological interventions (Table 
2). A recent meta-analysis by our group assessed the odds of 
initiation or continuation of pharmacological and lifestyle car-
diovascular preventive therapies in patients with non-zero ver-
sus zero CAC score detected on cardiac computed tomography 
[23]. In this meta-analysis of six studies [24-29] involving 
11,256 participants in a mean follow-up of 1.6 to 6 years, we 
found that identifying calcified coronary plaque, significantly 
increased the likelihood of initiation of aspirin and blood pres-
sure lowering medications, initiation and continuation of lipid 
lowering medications, as well as intensification of exercise and 
dietary changes. These findings remained significant after ad-
justment for baseline patient characteristics and cardiovascular 
risk factors in individual studies.
To date, several RCTs have investigated the effect of CAC 
scan versus no scan on preventive pharmacotherapies in asymp-
tomatic individuals [24,30-32]. O’Malley et al. [30] did not find 
the impact of CAC scan on change in 10-year Framingham risk 
score over 1 year among group of patients to whom CAC scan 
information was provided versus withheld. However, partici-
pants in this trial were asymptomatic active duty United States 
Army personnel, with very low cardiovascular risk at baseline 
(0 CAC score in 85.3% of patients), in whom an additional risk-
reduction would be hard to achieve. Similarly, a small RCT of 
56 postmenopausal women without known CAD did not show 
an independent benefit of CAC scanning on cardiovascular risk 
factor control that included systolic blood pressure and lipid 
profile (CAC <10 in 73.1% of 26 women who underwent CAC 
scan) [32]. It must be emphasized that the low risk populations 
in these studies are not fully representative of the population in 
which CAC scan is intended. Indeed, consistent evidence sup-
ports the concept that individuals who are at intermediate risk 
by traditional risk scores have the greatest potential for risk re-
classification and modification of primary prevention therapies. 
By comparison, Rozanski et al. [24], in Early Identification of 
Subclinical Atherosclerosis by Noninvasive Imaging Research 
(EISNER) trial, performed a large, well-designed RCT of 2,137 
middle-aged subjects with cardiovascular risk factors in whom 
a large proportion of the patients with CAC testing had a non-
zero CAC score (n=680/1,311, 52%). In this study CAC scan-
ning was associated with superior CAD risk factor control com-
pared to usual care alone. 
Whelton et al. [33] conducted an updated meta-analysis of the 
four available RCTs and found a non-significant trend towards 
reduction in blood pressure, lipid levels, and smoking cessation 
among individuals who had a CAC scan compared to those who 
were managed by standard care. However, the EISNER trial 
[24] showed that within the CAC scan group, there was signifi-
cant increase in aspirin, statin and blood pressure lowering 
medications in individuals with non-zero CAC. Therefore, ab-
normal CAC score, and not just merely the CAC scan itself, 
likely accounts for behavioral changes following CAC scan. A 
RCT by Mols et al. [34] further supports this view. They found 
that in stable chest pain patients with hyperlipidemia and no ob-
Table 2. Mechanisms by Which Coronary Artery Calcium Test-
ing May Improve Cardiovascular Outcomes
How does coronary artery calcium testing improve outcomes?
√ Improvement in risk factor profile
√ Intensification of preventive therapies
√ Better adherence to preventive therapies
√ Dietary modifications
√ Increased exercise
Blankstein R, et al.
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structive CAD who have CAC >70 on calcium scan, visualiza-
tion of CAC, and brief recommendations about risk modifica-
tion led to a favorable influence on plasma total cholesterol 
concentration and adherence to statin therapy.
WHAT ARE THE IMPLICATION OF CAC 
TESTING BEYOND CHD? 
Recent studies have shown that increased CAC is associated 
with higher rate of cerebrovascular accidents [35,36], heart fail-
ure [37,38], and atrial fibrillation [39]. In addition, compared to 
individuals who have no CAC, those with increased CAC are 
more likely to have other non-cardiac conditions such as cancer, 
chronic kidney disease, chronic obstructive pulmonary disease, 
and hip fractures [40].
THE ROLE OF CAC IN INDIVIDUALS WHO 
HAVE DIABETES
For more than a decade, the presence of diabetes has been con-
sidered a CHD risk equivalent. However, several recent studies 
have shown that the CVD risk of patients with diabetes is mark-
edly variable. A recent large, contemporary cohort showed that 
diabetes alone did not confer the same level of CHD risk as in-
dividuals with prior CHD. Compared to individuals without dia-
betes or CHD, the risk doubled among those with diabetes 
alone, but tripled among those with prior CHD alone. Impor-
tantly CHD event rates were very low among individuals with 
diabetes who were less than 40 years of age [41]. While these 
results suggest a potential role for further risk stratification 
among those with diabetes [42], prior trials using nuclear myo-
cardial perfusion imaging [43] or coronary CT angiography [44] 
have not shown any improvement in patient outcomes associat-
ed with screening. In part these negative results were due to the 
fact that event rates in these studies were lower than predicted, 
and medical therapy was highly prevalent, regardless of whether 
screening was performed or not. Accordingly, while there may 
remain an unproven role for screening very high risk individu-
als with diabetes using functional testing, in younger and lower 
risk individuals the role of screening may ultimately be to iden-
tify which individuals—despite their diabetes—have a suffi-
ciently low long-term risk that they can defer treatment with 
statins.
Supporting the potential role of CAC screening in diabetes or 
metabolic syndrome, Malik et al. [45] evaluated the association 
of CAC with CHD events in 6,603 people aged 45 to 84 years 
without clinical CVD in the MESA and risk factor-adjusted haz-
ard ratios for CHD for CAC 1 to 99 to ≥400 versus 0 in sub-
jects with neither metabolic syndrome nor diabetes ranged from 
2.6 to 9.5; in those with metabolic syndrome ranged from 3.9 to 
11.9; and in those with diabetes ranged from 2.9 to 6.2 (all 
P<0.05). Patients with metabolic syndrome or diabetes and a 
CAC score of 0 had a projected annual CHD event rate of 0.4% 
and 0.8%, respectively, whereas those with CAC score of >400 
had annual CHD event rate of 4.6% and 5.1%, respectively. Di-
abetes mellitus has traditionally been considered as a CHD risk 
equivalent. However, 45% of patients with metabolic syndrome 
and 38% patients with diabetes in this study had a CAC score of 
0 with annual CHD event rate similar to those without these 
conditions (Fig. 8). 
These findings imply that CAC testing in these patients could 
help with risk-reclassification of a significant proportion of pa-
tients with diabetes or metabolic syndrome. Nevertheless, the 
use of routine CAC screening in individuals with diabetes re-
mains uncertain, and a trial assessing the impact of CAC testing 
in this population has not been conducted. Such a trial would 
have to be based on the fact that the greatest utility of CAC test-
ing is to identify those individuals who are being considered for 
statin therapy, in whom there is a strong patient preference to 
avoid statins (if the CAC score is 0), but a willingness to initiate 
therapy if coronary atherosclerosis is detected.
FUTURE ROLE OF CAC BEYOND STATINS
In the future, additional preventive therapies beyond statins may 
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Fig. 8. Annualized unadjusted cardiovascular disease (CVD) event 
rates in Multi-Ethnic Study of Atherosclerosis (MESA) stratified by 
coronary artery calcification (CAC) and the presence of diabetes 
mellitus (DM), metabolic syndrome (MetS), or neither. Adapted 
from Malik et al. [45], with permission from American Diabetes 
Association.
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be considered for selected individuals who do not have known 
CVD. Realizing such therapies are likely to be more expensive 
and may be associated with more adverse effects, it is plausible 
that the allocation of newer therapies may be improved by using 
CAC testing in order to identify those with the highest risk, who 
therefore stand to have the greatest reduction in events. Realiz-
ing this potential role, future drug development trials may bene-
fit from using CAC testing as a way to better enrich the popula-
tion tested.
CONCLUSIONS
CAC testing is now well recognized as a simple, reproducible, 
and inexpensive test to assess for the presence or absence of 
coronary atherosclerosis. Most individuals who have a CAC=0 
have a very low risk of future cardiovascular events over the 
next 10 to 15 years and can elect to defer statin therapy and in-
stead focus on lifestyle intervention. On the other hand, for 
those who are being considered for statin therapy, the presence 
of CAC—irrespective of whether other risk factors are present 
or absent, and regardless of age—can be used to provide a more 
precise risk assessment, and consequently provide a more com-
pelling case for using pharmacotherapy.
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